These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30644143)

  • 1. MRI Features Associated with TERT Promoter Mutation Status in Glioblastoma.
    Ivanidze J; Lum M; Pisapia D; Magge R; Ramakrishna R; Kovanlikaya I; Fine HA; Chiang GC
    J Neuroimaging; 2019 May; 29(3):357-363. PubMed ID: 30644143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas.
    Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
    Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastoma.
    Ersoy TF; Keil VC; Hadizadeh DR; Gielen GH; Fimmers R; Waha A; Heidenreich B; Kumar R; Schild HH; Simon M
    Neuroradiology; 2017 Dec; 59(12):1223-1231. PubMed ID: 28894890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
    Yamashita K; Hatae R; Hiwatashi A; Togao O; Kikuchi K; Momosaka D; Yamashita Y; Kuga D; Hata N; Yoshimoto K; Suzuki SO; Iwaki T; Iihara K; Honda H
    Diagn Interv Imaging; 2019; 100(7-8):411-419. PubMed ID: 30948344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain regions associated with telomerase reverse transcriptase promoter mutations in primary glioblastomas.
    Fan X; Wang Y; Liu Y; Liu X; Zhang C; Wang L; Li S; Ma J; Jiang T
    J Neurooncol; 2016 Jul; 128(3):455-62. PubMed ID: 27230769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep Learning Radiomics for the Assessment of Telomerase Reverse Transcriptase Promoter Mutation Status in Patients With Glioblastoma Using Multiparametric MRI.
    Zhang H; Zhang H; Zhang Y; Zhou B; Wu L; Lei Y; Huang B
    J Magn Reson Imaging; 2023 Nov; 58(5):1441-1451. PubMed ID: 36896953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiparametric MRI-based fusion radiomics for predicting telomerase reverse transcriptase (TERT) promoter mutations and progression-free survival in glioblastoma: a multicentre study.
    Zhang H; Zhang H; Zhang Y; Zhou B; Wu L; Yang W; Lei Y; Huang B
    Neuroradiology; 2024 Jan; 66(1):81-92. PubMed ID: 37978079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI Features May Predict Molecular Features of Glioblastoma in
    Park CJ; Han K; Kim H; Ahn SS; Choi D; Park YW; Chang JH; Kim SH; Cha S; Lee SK
    AJNR Am J Neuroradiol; 2021 Mar; 42(3):448-456. PubMed ID: 33509914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging.
    Ahn SS; Shin NY; Chang JH; Kim SH; Kim EH; Kim DW; Lee SK
    J Neurosurg; 2014 Aug; 121(2):367-73. PubMed ID: 24949678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting TERT promoter mutation status using
    Yamashita K; Hatae R; Kikuchi K; Kuga D; Hata N; Yamamoto H; Obara M; Yoshimoto K; Ishigami K; Togao O
    Neuroradiology; 2023 Aug; 65(8):1205-1213. PubMed ID: 37308686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A radiomics-based nomogram may be useful for predicting telomerase reverse transcriptase promoter mutation status in adult glioblastoma.
    Li Y; Chen L; Huang L; Li X; Huang Q; Tang L; Huang Z; Zhu L; Li T
    Brain Behav; 2024 May; 14(5):e3528. PubMed ID: 38798094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
    Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ
    Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma.
    Lasocki A; Tsui A; Gaillard F; Tacey M; Drummond K; Stuckey S
    J Clin Neurosci; 2017 May; 39():170-175. PubMed ID: 28214089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.
    Diplas BH; He X; Brosnan-Cashman JA; Liu H; Chen LH; Wang Z; Moure CJ; Killela PJ; Loriaux DB; Lipp ES; Greer PK; Yang R; Rizzo AJ; Rodriguez FJ; Friedman AH; Friedman HS; Wang S; He Y; McLendon RE; Bigner DD; Jiao Y; Waitkus MS; Meeker AK; Yan H
    Nat Commun; 2018 May; 9(1):2087. PubMed ID: 29802247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma.
    Liu X; Mangla R; Tian W; Qiu X; Li D; Walter KA; Ekholm S; Johnson MD
    J Neurooncol; 2017 Dec; 135(3):553-560. PubMed ID: 28889246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
    Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
    Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value.
    Hwang I; Choi SH; Park CK; Kim TM; Park SH; Won JK; Kim IH; Lee ST; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
    AJNR Am J Neuroradiol; 2020 Jan; 41(1):49-56. PubMed ID: 31806595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.
    Matsumura N; Nakajima N; Yamazaki T; Nagano T; Kagoshima K; Nobusawa S; Ikota H; Yokoo H
    Neuropathology; 2017 Feb; 37(1):58-63. PubMed ID: 27302309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TERT promoter mutations in primary and secondary glioblastomas.
    Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H
    Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
    Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
    Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.